Gsa Capital Partners LLP Sellas Life Sciences Group, Inc. Transaction History
Gsa Capital Partners LLP
- $1.2 Billion
- Q3 2025
A detailed history of Gsa Capital Partners LLP transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 518,995 shares of SLS stock, worth $742,162. This represents 0.07% of its overall portfolio holdings.
Number of Shares
518,995
Previous 426,584
21.66%
Holding current value
$742,162
Previous $934,000
10.49%
% of portfolio
0.07%
Previous 0.07%
Shares
5 transactions
Others Institutions Holding SLS
# of Institutions
100Shares Held
27.8MCall Options Held
3.85MPut Options Held
126K-
Vanguard Group Inc Valley Forge, PA6.84MShares$9.78 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX6.03MShares$8.63 Million1.59% of portfolio
-
Marshall Wace, LLP London, X02.36MShares$3.37 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.26MShares$3.24 Million0.0% of portfolio
-
State Street Corp Boston, MA1.36MShares$1.95 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $29.4M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...